Liu Jieqiong, Xing Rongge, Shao Jiakang, Jiao Shunchang
Medical School of Chinese PLA, Beijing, 100853, People's Republic of China.
Cangzhou Central Hospital, Cangzhou, Hebei Province, 061000, People's Republic of China.
Int J Gen Med. 2023 Nov 3;16:5077-5087. doi: 10.2147/IJGM.S437957. eCollection 2023.
Recurrent metastasis after radical resection in patients of colorectal cancer (CRC) is a great challenge for the world, in which genomic alterations play a major role in tumorigenesis. MUC4 plays a significant role in recurrence and metastasis in tumor. This study is aimed at exploring the association between MUC4 variants and metastatic recurrence of CRC.
Forty-seven patients relapsing with metastasis and 37 patients remaining disease-free postoperatively were enrolled. Next-generation sequencing (NGS) detected mutations. Mutation and mRNA expression data were downloaded from TCGA and cBioPortal databases. We analyzed the relationship between MUC4 variants and clinical parameters, as well as possible molecular mechanisms.
MUC4 variants rs56359992 and rs781124621 were associated with survival in patients with CRC. Rs56359992 was more common in patients with metastatic recurrence. MAPK pathway, PI3K-Akt pathway, JAK-STAT pathway, cell cycle, WNT pathway and mTOR pathway were found to correlate with MUC4 mutation by GO/KEGG analysis, as well as resting and activated mast cell related to MUC4 mutation by CIBERSORT analysis.
Genetic variants of MUC4 with CRC may constitute a molecular signature of metastatic recurrence. MUC4 may become a new target for the treatment of CRC recurrence.
结直肠癌(CRC)患者根治性切除术后的复发转移是全球面临的重大挑战,其中基因组改变在肿瘤发生中起主要作用。MUC4在肿瘤的复发和转移中起重要作用。本研究旨在探讨MUC4变异与CRC转移复发之间的关联。
纳入47例发生转移复发的患者和37例术后无病生存的患者。采用二代测序(NGS)检测突变。从TCGA和cBioPortal数据库下载突变和mRNA表达数据。我们分析了MUC4变异与临床参数之间的关系以及可能的分子机制。
MUC4变异rs56359992和rs781124621与CRC患者的生存相关。rs56359992在转移复发患者中更常见。通过GO/KEGG分析发现MAPK通路、PI3K-Akt通路、JAK-STAT通路、细胞周期、WNT通路和mTOR通路与MUC4突变相关,通过CIBERSORT分析发现静息和活化肥大细胞也与MUC4突变相关。
CRC中MUC4的基因变异可能构成转移复发的分子特征。MUC4可能成为治疗CRC复发的新靶点。